Explore

Trendline Trendline
Kanvas Biosciences Secures $48M to Enhance Spatial Biology and Cancer Trials

Kanvas Biosciences Secures $48M to Enhance Spatial Biology and Cancer Trials

Kanvas Biosciences Secures $48M to Enhance Spatial Biology and Cancer Trials
Trendline Trendline
Cytospire Secures $83 Million for Innovative T-Cell Engager Platform

Cytospire Secures $83 Million for Innovative T-Cell Engager Platform

Cytospire Secures $83 Million for Innovative T-Cell Engager Platform
Trendline Trendline
Curis to Announce Q1 2026 Financial Results and Host Webcast

Curis to Announce Q1 2026 Financial Results and Host Webcast

Curis to Announce Q1 2026 Financial Results and Host Webcast
Trendline Trendline
Nuvectis Pharma Reports Increased Net Loss in Q1 2026

Nuvectis Pharma Reports Increased Net Loss in Q1 2026

Nuvectis Pharma Reports Increased Net Loss in Q1 2026
Trendline Trendline
Merck Completes Acquisition of Terns Pharmaceuticals, Expanding Oncology Pipeline

Merck Completes Acquisition of Terns Pharmaceuticals, Expanding Oncology Pipeline

Merck Completes Acquisition of Terns Pharmaceuticals, Expanding Oncology Pipeline
Trendline Trendline
Allarity Therapeutics Advances Stenoparib Manufacturing for Phase 3 Trials in Ovarian Cancer

Allarity Therapeutics Advances Stenoparib Manufacturing for Phase 3 Trials in Ovarian Cancer

Allarity Therapeutics Advances Stenoparib Manufacturing for Phase 3 Trials in Ovarian Cancer
Trendline Trendline
LTZ Therapeutics Secures $38 Million to Advance Immunotherapy Pipeline

LTZ Therapeutics Secures $38 Million to Advance Immunotherapy Pipeline

LTZ Therapeutics Secures $38 Million to Advance Immunotherapy Pipeline
Trendline Trendline
Kanvas Biosciences Secures $48M Series A to Advance Microbiome Therapeutics for Cancer Patients

Kanvas Biosciences Secures $48M Series A to Advance Microbiome Therapeutics for Cancer Patients

Kanvas Biosciences Secures $48M Series A to Advance Microbiome Therapeutics for Cancer Patients
Trendline Trendline
IDEAYA Biosciences Reports Positive Results and Business Updates for Q1 2026

IDEAYA Biosciences Reports Positive Results and Business Updates for Q1 2026

IDEAYA Biosciences Reports Positive Results and Business Updates for Q1 2026
Trendline Trendline
ADC Therapeutics Reports Q1 2026 Financial Results and Operational Updates

ADC Therapeutics Reports Q1 2026 Financial Results and Operational Updates

ADC Therapeutics Reports Q1 2026 Financial Results and Operational Updates
Trendline Trendline
Nuvectis Pharma Reports Increased Net Loss in Q1 2026 Amid Clinical Expansion

Nuvectis Pharma Reports Increased Net Loss in Q1 2026 Amid Clinical Expansion

Nuvectis Pharma Reports Increased Net Loss in Q1 2026 Amid Clinical Expansion
Trendline Trendline
Summit Shares Plummet as Cancer Drug Fails Early Survival Benchmark

Summit Shares Plummet as Cancer Drug Fails Early Survival Benchmark

Summit Shares Plummet as Cancer Drug Fails Early Survival Benchmark